A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate

Back to Search
Print
Bookmark Trial

NCT00620685

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Phoenix, Arizona, 85013, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Arthritis, Rheumatoid
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Adult with RA for at least 6 months

- Stable weekly dosage of oral methotrexate 12.5- 25 mg/week

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Severe, progressive and/or uncontrolled other disease


- Chronic or recent serious infection; current infection


- Concomitant use of RA therapy other than methotrexate with some exceptions

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Arthritis, RheumatoidStudy of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate
NCT00628095
  1. Mesa, Arizona
  2. Debary, Florida
  3. Lake Mary, Florida
  4. Tampa, Florida
  5. Avon, Indiana
  6. New Orleans, Louisiana
  7. Frederick, Maryland
  8. Columbia, Missouri
  9. Columbia, Missouri
  10. Reno, Nevada
  11. Cincinnati, Ohio
  12. Spokane, Washington
  13. Providencia, Santiago, RM
  14. Ceska Lipa,
  15. Praha 2,
  16. Praha 4,
  17. Incheon,
  18. Pusan,
  19. Mexico, D.f.
  20. Krakow,
  21. Poznan,
  22. Poznan,
  23. Santiago de Compostela, A Coruña
  24. A Coruña,
  25. Madrid,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Arthritis, RheumatoidEtanercept (Enbrel) Special Investigation (Regulatory Post Marketing Commitment Plan)
NCT01230177
  1. Sendai, Miyagi
ALL GENDERS
16 Years+
years
MULTIPLE SITES
Arthritis, RheumatoidStudy To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis
NCT00440492
  1. Los Angeles, California
  2. Palo Alto, California
  3. Lake Success, New York
  4. Rochester, New York
  5. Charlotte, North Carolina
  6. Columbus, Ohio
  7. Vancouver, British Columbia
  8. Mississauga, Ontario
  9. Montreal, Quebec
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Arthritis, RheumatoidDose-Escalating Multiple Dose Study of PD-0360324 in Combination With Methotrexate in Patients With Rheumatoid Arthritis
NCT00550355
  1. Peoria, Arizona
  2. Daytona Beach, Florida
  3. Port Orange, Florida
  4. Overland Park, Kansas
  5. Overland Park, Kansas
  6. Frederick, Maryland
  7. Lansing, Michigan
  8. Duncansville, Pennsylvania
  9. Dallas, Texas
  10. Buenos Aires,
  11. Pleven,
  12. Sofia,
  13. Sofia,
  14. Brno,
  15. Praha 4,
  16. Mexico, D.f.
  17. Mexico, DF
  18. Bialystok,
  19. Bialystok,
  20. Krakow,
  21. Krakow,
  22. Warszawa,
  23. Wroclaw,
  24. Piestany,
  25. Santiago de Compostela, A Coruña
ALL GENDERS
21 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate
Official Title  ICMJE A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Safety And Pharmacokinetic Profile Of 1 And 5 Mg Ph-797804 Administered Once Daily In Subjects With Rheumatoid Arthritis Who Are Taking Oral Methotrexate
Brief Summary The hypothesis of this study is that the p38 inhibitor (PH-797804) will be safe and well tolerated in subjects with rheumatoid arthritis who are taking methotrexate and will not effect the blood levels of methotrexate.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Arthritis, Rheumatoid
Intervention  ICMJE
  • Drug: Placebo
    Tablet, once daily for 4 weeks
  • Drug: PH-797804
    Tablet, 1 mg PH-797804, once daily for 4 weeks
  • Drug: PH-797804
    Tablet, 5 mg PH-797804, once daily for 4 weeks
Study Arms  ICMJE
  • Placebo Comparator: 1
    Intervention: Drug: Placebo
  • Experimental: 2
    Intervention: Drug: PH-797804
  • Experimental: 3
    Intervention: Drug: PH-797804
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 7, 2008)		27
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE October 2008
Actual Primary Completion Date October 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Adult with RA for at least 6 months
  • Stable weekly dosage of oral methotrexate 12.5- 25 mg/week

Exclusion Criteria:

  • Severe, progressive and/or uncontrolled other disease
  • Chronic or recent serious infection; current infection
  • Concomitant use of RA therapy other than methotrexate with some exceptions
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00620685
Other Study ID Numbers  ICMJE A6631005
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP